Kynmobi Safe, Effective for ‘Off’ Periods Over Long Term, Ongoing Trial Reports
Sep 15, 2020 07:00 am | Marisa Wexler
 Sunovion‘s Kynmobi (apomorphine hydrochloride), a sublingual film treatment for “off” episodes in people with Parkinson’s disease, has a manageable safety profile and maintains efficacy over up to nearly a year of use, interim data from an ongoing Phase 3 trial show. Findings were presented at MDS Virtual Congress 2020 in the study, “A Long-Term Safety, Tolerability, […]
The post Kynmobi Safe, Effective for ‘Off’ Periods Over Long Term, Ongoing Trial Reports appeared first on Parkinson's News Today. |
Engineers with Michigan State University (MSU) are developing diamond-based electrodes that might detect early warning signs of neurodegenerative diseases such as Parkinson’s in a living brain. MSU researchers Wen Li and Erin Purcell have received $3.4 million in funding from the National Institutes of Health and an MSU Strategic Partnership Grant to conduct preclinical work evaluating the safety, durability, […]
Supernus Pharmaceuticals has submitted a new drug application to the U.S. Food and Drug Administration (FDA) seeking approval of SPN-830, its apomorphine infusion pump, the company said. If approved, the pump will be used for the continuous treatment of on-off episodes in adults with Parkinson’s disease who continue to experience motor symptoms after treatment with oral levodopa and […]
Mutations in the PARK7 gene, known to cause early onset Parkinson’s disease, result in low levels of a protein called DJ-1 that is essential for nerve cell health, a study revealed. In fixing a protein processing malfunction in cells derived from members of a single family who carried a particular mutation in this gene, a team […]
